Indoco Remedies Secures EU GMP Certification for Baddi Facility After Malta Medicines Authority Audit
Indoco Remedies Ltd. announced that its manufacturing facility for solid oral dosage form (Unit I) in Baddi has successfully received EU GMP certification from the Malta Medicines Authority. The facility underwent inspection by the Authority spanning from January 29, 2026, to February 3, 2026.The certification confirms that the Baddi unit complies with the Good Manufacturing Practice requirements outlined in the EC Directive, marking a significant milestone in the company's global quality compliance efforts.
Commenting on the development, Ms. Aditi Panandikar, Managing Director of Indoco Remedies Ltd., stated, "This approval from the Malta Medicine Authority further reflects Indoco's strong commitment to quality, compliance and adherence to global regulatory standards. We are focused on maintaining the highest quality standards while catering to our customers in India and globally."
Operational Profile and Global Reach
Indoco Remedies Ltd. is described as a fully integrated, research-oriented pharmaceutical company with a strong global presence. The company maintains a robust operational capacity, generating more than 109 million prescriptions annually from over 2,50,000 doctors across various specialties in India and internationally.As of its latest data, Indoco's turnover stands at US$ 175 million, supported by a workforce of over 6000 employees, which includes more than 300 skilled scientists and field staff.
The company operates a total of 10 manufacturing facilities, comprising 6 units for FDFs and 4 units for APIs. These operations are further supported by a state-of-the-art Research and Development Centre and a CRO facility. Indoco's manufacturing capabilities have received approvals from major regulatory authorities, including the USFDA and the UK-MHRA.
Indoco maintains 10 domestic marketing divisions and possesses a diverse brand portfolio spanning multiple therapeutic segments, including Gastro-intestinal, Respiratory, Anti-Infectives, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, and Gynaecology.
INDOCO Stock Price Movement
Shares of Indoco Remedies Limited are edging higher to ₹228 as of 11:06 AM today, gaining 0.90% and marking a daily rise of ₹2.03. The stock shows strong market interest, executing trades on a volume of 23,147 shares in the live market.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.